Marina Ines Flamini

Dr. Marina Ines Flamini

Laboratorio de Biología Tumoral, Instituto de Medicina y Biología Experimental de Cuyo (IMBECU, CCT conicet, Mendoza), Mendoza, Argentina
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2014 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MFMarina Ines Flamini
Marina Ines Flamini
GGGisel Valeria Gauna
Gisel Valeria Gauna
MSMayra Lis Sottile
Mayra Lis Sottile
SNSilvina B Nadin
Silvina B Nadin
ASAngel Matias Sanchez
Angel Matias Sanchez
LVLaura María Vargas‐Roig
Laura María Vargas‐Roig
Breast cancer is the most common malignancy in women and the appearance of distant metastases produces the death in 98% of cases. The retinoic acid receptor β (RARβ) is not expressed in 50% of invasive breast carcinoma compared with normal tissue and it has been associated with lymph node metastasis. Our hypothesis is that RARβ protein participates in the metastatic process. T47D and MCF7 breast cancer cell lines were used to perform viability assay, immunobloting, migration assays, RNA interference and immunofluorescence. Administration of retinoic acid (RA) in breast cancer cells induced RARβ gene expression that was greatest after 72 hrs with a concentration 1 μM. High concentrations of RA increased the expression of RARβ causing an inhibition of the 60% in cell migration and significantly decreased the expression of migration‐related proteins [moesin, c‐Src and focal adhesion kinase (FAK)]. The treatment with RARα and RARγ agonists did not affect the cell migration. On the contrary, the addition of the selective retinoid RARβ‐agonist (BMS453) significantly reduced cell migration comparable to RA inhibition. When RARβ gene silencing was performed, the RA failed to significantly inhibit migration and resulted ineffective to reduce moesin, c‐Src and FAK expressions. RARβ is necessary to inhibit migration induced by RA in breast cancer cells modulating the expression of proteins involved in cell migration.

1 July 2016 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
ASAngel Matías Sanchez
Angel Matías Sanchez
JSJorge Eduardo Shortrede
Jorge Eduardo Shortrede
LVLaura María Vargas-Roig
Laura María Vargas-Roig
MFMarina Ines Flamini
Marina Ines Flamini

29 May 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
FVFiorella Vanderhoeven
Fiorella Vanderhoeven
ARAnalía Lourdes Redondo
Analía Lourdes Redondo
AMAna Laura Martinez
Ana Laura Martinez
LVLaura María Vargas-Roig
Laura María Vargas-Roig
ASAngel Matias Sanchez
Angel Matias Sanchez
MFMarina Ines Flamini
Marina Ines Flamini
Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells

1 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ACAna Carla Castro-Guijarro
Ana Carla Castro-Guijarro
ÁSÁngel Matias Sanchez
Ángel Matias Sanchez
MFMarina Ines Flamini
Marina Ines Flamini
Breast cancer (BC) is the most common malignancy among women worldwide. Around 15–25% of BC overexpress the human epidermal growth factor receptor 2 (HER2), which is associated with a worse prognosis and shortened disease-free survival. Therefore, anti-HER2 therapies have been developed, such as monoclonal antibodies (trastuzumab, Tz), antibody–drug conjugates (ado-trastuzumab emtansine, T-DM1), and pharmacological inhibitors of tyrosine kinase activity (lapatinib, Lp). Although Tz, the standard treatment, has significantly improved the prognosis of patients, resistance still affects a significant population of women and is currently a major challenge in clinical oncology. Therefore, this study aims to identify potential biomarkers to predict disease progression (prognostic markers) and the efficacy of Tz treatment (predictive markers) in patients with HER2+ BC. We hypothesize that proteins involved in cell motility are implicated in Tz-resistance. We aim to identify alterations in Tz-resistant cells to guide more efficient oncologic decisions. By bioinformatics, we selected candidate proteins and determined how their expression, localization, and the process they modulate were affected by anti-HER2 treatments. Next, using HER2+ BC patients’ data, we assessed these proteins as prognostic and predictive biomarkers. Finally, using Tz-resistant cells, we evaluated their roles in Tz response. We identified deregulated genes associated with cell motility in Tz/T-DM1-resistant vs. -sensitive cells. We showed that Tz, T-DM1, and Lp decrease cell viability, and their effect is enhanced in combinations. We determined synergism between Tz/T-DM1 and Lp, making possible a dose reduction of each drug to achieve the same therapeutic effect. We found that combinations (Tz/T-DM1 + Lp) efficiently inhibit cell adhesion and migration. Furthermore, we demonstrated the induction of FAK nuclear and cortactin peri-nuclear localization after T-DM1, Lp, and Tz/T-DM1 + Lp treatments. In parallel, we observed that combined treatments downregulate proteins essential for metastatic dissemination, such as SRC, FAK, and paxillin. We found that low vinculin (VCL) and cortactin (CTTN) mRNA expression predicts favorable survival rates and has diagnostic value to discriminate between Tz-sensible and Tz-resistant HER2+ BC patients. Finally, we confirmed that vinculin and cortactin are overexpressed in Tz-resistance cells, SKBR3-RTz. Moreover, we found that Tz plus FAK/paxillin/cortactin-silencing reduced cell adhesion/migration capacity in Tz-sensitive and -resistant cells. In conclusion, we demonstrate that combined therapies are encouraging since low doses of Tz/T-DM1 + Lp inhibit metastatic processes by downregulating critical protein expression and affecting its subcellular localization. We propose that vinculin and cortactin might contribute to Tz-sensibility/resistance in BC cells. Finally, we identify potential prognostic and predictive biomarkers that are promising for personalized BC management that would allow efficient patient selection in order to mitigate resistance and maximize the safety and efficacy of anti-HER2 therapies.

6 December 2021 in Research Square
Verified
Preprint
Open access
PDF file
ACAna Carla Guijarro Castro
Ana Carla Guijarro Castro
JMJoselina Mondaca
Joselina Mondaca
JFJuan Manuel Fernandez-Muñoz
Juan Manuel Fernandez-Muñoz
FVFiorella Vanderhoeven
Fiorella Vanderhoeven
IUIvonne Uzair
Ivonne Uzair
MFMarina Ines Flamini
Marina Ines Flamini
All-trans retinoic acid (RA) is the primary metabolite of vitamin A and controls the development and homeostasis of organisms and tissues. RA and its natural and synthetic derivatives, known as retinoids, are promising agents in treating and chemoprevention different neoplasias, including breast cancer (BC). Focal adhesion kinase (FAK) is a crucial regulator of cell migration, and its overexpression is associated with the metastatic behavior of tumors. Thus, pharmaceutical FAK inhibitors (FAKi) have been developed to counter its action. In this work, we hypothesize that RA plus FAKi (RA+FAKi) approach could improve inhibition of tumor progression. By in silico analysis, we confirmed RARA, SRC, and PTK2 (encoding RARα, Src, and FAK, respectively) overexpression in all breast cells tested. In metastatic BC cells, we reveal that genes encoding proteins that FAK directly or indirectly modulates are deregulated compared to normal cells. We showed a different pattern of genes up/down-regulated between RA-resistant and RA-sensitive BC cells. In addition, we demonstrated that both RA-resistant BC cells (MDA-MB-231 and MDA-MB-468) display the same behavior after RA treatment, modulating the expression of genes involved in Src-FAK signaling. Furthermore, we demonstrated that although RA and FAKi administered separately decrease viability, adhesion, and migration in mammary adenocarcinoma LM3 cells, their combination exerts a higher effect. We also evidenced that RA effects are extrapolated to other cancer cells, including the human cervical carcinoma cells HeLa. In an orthotopic assay of LM3 tumor growth, RA and FAKi administered separately reduce tumor growth; however, the combined treatment induces the more potent inhibition increasing mice survival. Moreover, in an experimental metastatic assay, RA significantly reduces metastatic lung dissemination of LM3 cells. Overall, these results indicate that RA resistance would reflect deregulation of most RA-target genes, including genes encoding components of the Src-FAK pathway. Our study demonstrates that RA plays an essential role in disrupting BC tumor growth and metastatic dissemination in vitro and in vivo by controlling FAK expression and localization. RA plus FAKi exacerbated these effects suggesting that the sensibility to RA therapies could be increased with FAKi coadministration in BC tumors.

22 May 2026 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
GBGustavo Adolfo Barraza
Gustavo Adolfo Barraza
JMJoselina Magali Mondaca
Joselina Magali Mondaca
JFJuan Manuel Fernandez-Muñoz
Juan Manuel Fernandez-Muñoz
BVBruno Mariano Vinante
Bruno Mariano Vinante
MFMarina Ines Flamini
Marina Ines Flamini
ÁSÁngel Matias Sanchez
Ángel Matias Sanchez
The tumor suppressor protein phosphatase 2A (PP2A) plays a crucial role in regulating oncogenic signaling. Its inactivation, specifically through inhibitory phosphorylation at Tyr307 mediated by SET and CIP2A, contributes to breast cancer (BC) progression. Modulation of these interactions represents a promising pharmacological strategy to restore PP2A function. We integrated computational approaches with experimental validation to analyse SET/CIP2A mechanisms and explore how PP2A reactivation suppresses tumor progression. Molecular docking and dynamics simulations showed that the SET inhibitor/FTY-720 forms stable hydrogen bond networks with SET, disrupting its interaction with PP2A. In contrast, CIP2A suppressor/erlotinib interacts with CIP2A through weaker hydrophobic and π-interactions. Protein–protein interaction analyses indicate reduced SET/CIP2A binding to PP2A upon treatment, supporting a structural basis for PP2A reactivation. Gene expression analyses revealed upregulation of PP2A, SET, CIP2A, and cytoskeletal markers in tumor and metastatic tissues. Studies on Triple Negative Breast Cancer (TNBC) cells showed that FTY-720 and erlotinib significantly reduce PP2A-Tyr307 phosphorylation, restoring its activity. Additionally, both compounds decreased c-Myc levels and inhibited Src/FAK/paxillin/PAK1 and ERK signaling, attenuating migratory and proliferative pathways. Our findings identify the SET/CIP2A–PP2A axis as a pharmacological target for the design of next-generation PP2A activators, highlighting the potential of inhibition as a therapeutic strategy to counteract TNBC progression.